Genetic polymorphisms in C-reactive protein increase cancer susceptibility
Peiliang Geng1, Rina Sa1, Jianjun Li1
1Department of Oncology and Southwest Cancer Center, Southwest Hospital Third Military Medical University, 29 Gaotanyan Main Street, Chongqing 400038, China.
Scientific Reports
|February 26, 2016
Summary
Certain C-reactive protein (CRP) gene polymorphisms, specifically +942G>C and 1846C>T, are linked to an increased risk of developing cancer, particularly colorectal cancer.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Elevated C-reactive protein (CRP) levels are implicated in human cancer development.
- Genetic variations (polymorphisms) within the CRP gene may influence cancer susceptibility.
Purpose of the Study:
- To investigate whether CRP gene polymorphisms (+942G>C and 1846C>T) modify inherited susceptibility to cancer.
- To systematically review and meta-analyze existing studies on CRP gene polymorphisms and cancer risk.
Main Methods:
- Systematic literature search for case-control studies on CRP gene polymorphisms and cancer.
- Meta-analysis of 8 eligible studies.
- Analysis of specific genotypes (+942G>C and 1846C>T) and their association with cancer risk.
Main Results:
- The CC genotype at the +942G>C locus was associated with a nearly 4-fold increased cancer risk.
- A significant association was observed for colorectal cancer.
- The 1846C>T polymorphism showed an increased cancer risk with the TT genotype (OR=1.15-1.17).
- These associations were particularly noted in Caucasian populations.
Conclusions:
- Both +942G>C and 1846C>T polymorphisms in the CRP gene may play a role in cancer susceptibility.
- CRP gene variants could be potential biomarkers for cancer risk assessment.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
01:33Cancer-Critical Genes I: Proto-oncogenes
11.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.8K
01:33Cancer-Critical Genes I: Proto-oncogenes
6.0K
6.0K
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:05Single Nucleotide Polymorphisms-SNPs
19.7K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.7K